The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1450
Statins and Diabetes Risk
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

In 2012, the FDA required manufacturers of HMG-CoA reductase inhibitors (statins) to add a warning to their labels about reports of increased blood glucose and glycosylated hemoglobin (HbA1c) levels.1 Since then, several new studies have been published.

MECHANISM — No mechanism for a diabetogenic effect of statins has been established. Some investigators have proposed that statins may cause an immune response that interferes with insulin signaling.2

NEW-ONSET DIABETES RISK — A meta-analysis of 5 primary or secondary cardiovascular prevention studies in a total of 51,619 non-diabetic patients, with median follow-up times ranging from 1.9-5.0 years, found that 4.0% of patients taking statins and 3.5% of those taking placebo developed diabetes.3 In another meta-analysis of 13 studies ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Statins and Diabetes Risk
Article code: 1450a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian